Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.36 USD
Change Today 0.00 / 0.00%
Volume 0.0
EQUR On Other Exchanges
As of 8:10 PM 08/21/15 All times are local (Market data is delayed by at least 15 minutes).

e- qure corp (EQUR) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/9/14 - $3.50
52 Week Low
06/24/15 - $0.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for E- QURE CORP (EQUR)

Related News

No related news articles were found.

e- qure corp (EQUR) Related Businessweek News

No Related Businessweek News Found

e- qure corp (EQUR) Details

E-Qure Corp. focuses on the development, commercialization, and distribution of bioelectrical signal therapy (BST) devices in the United States. Its BST device uses patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The company was formerly known as ADB International Group, Inc. and changed its name to E-Qure Corp. in August 2014. E-Qure Corp. was incorporated in 1988 and is based in New York, New York.

1 Employees
Last Reported Date: 05/21/15
Founded in 1988

e- qure corp (EQUR) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Chief Technology Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

e- qure corp (EQUR) Key Developments

E-Qure Corp. Enters into Distribution Agreement with Chemipal Ltd

On July 30, 2015, E-Qure Corp. entered into an exclusive distribution agreement with Chemipal Ltd. Under the Distribution Agreement, the company has granted Chemipal exclusive distribution rights to the company's medical device for the treatment of chronic wounds and the ac Companying disposable electrodes in Israel and the parties have agreed as follows: the company will supply the Distributor with an initial inventory of 40 BST Devices and 1,200 disposable electrodes on a consignment basis; the company will re-supply the Distributor with Products from time-to-time, based upon payment by the Distributor to the company; based upon demand for the Products, the parties will reevaluate and increase the size of the inventory as demand for the Products increase; the Distributor will use the BST Device for treatment of patients and rent the BST Device to hospitals, long-term care facilities, medical centers and clinics and other potential users; proceeds from BST Device rentals and electrode sales will be made to the company on a monthly basis and the revenues from rental and sale of the Products will be divided equally between the Company and the Distributor. The Distribution Agreement is for an initial term of 10 years, subject to a minimum quota for a period of 2 consecutive years, and the Company has the right to terminate the Distribution Agreement by six months prior written notice to the Distributor. The Initial Term shall be subject to automatic 5 year extensions unless either party gives a written termination notice 12 months prior to the expiration of any term.

E-Qure Corp. Presents at Virtual Investor Conference July 2015, Jul-09-2015 09:15 AM

E-Qure Corp. Presents at Virtual Investor Conference July 2015, Jul-09-2015 09:15 AM. Speakers: Ron Weissberg, Chairman.

E-Qure Corp. Signs First Distribution Agreement with Rubifarm S.A

E-Qure Corp. announced that the Company has signed its first distribution agreement with Rubifarm S.A. The agreement goes into effect immediately. After conducting preliminary market research, testing the device, and securing regulatory approval, E-QURE and Rubifarm entered into agreement where Rubifarm S.A. would undertake a minimum electrodes purchasing obligation of $50,000 for the first year, growing up to a minimum of $1,000,000 after 5 years. Local regulatory process has put the agreement into effect. In addition to purchase obligations, the distribution agreement defines the commercial terms of the relationship. In principle, devices will be rented to hospitals and clinics at a small monthly monetary rate to cover service and repairs, while the distributor will sell disposable electrodes on 'treatment days' basis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EQUR:US $0.36 USD 0.00

EQUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EQUR.
View Industry Companies

Industry Analysis


Industry Average

Valuation EQUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact E- QURE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at